{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T21:24:04Z","timestamp":1772400244852,"version":"3.50.1"},"reference-count":83,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2011,6,28]],"date-time":"2011-06-28T00:00:00Z","timestamp":1309219200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2011,9]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>For nearly 50\u2003years, the goal of the World Federation of Hemophilia (WFH) has been to achieve \u2018Treatment for All\u2019 patients with inherited bleeding disorders, regardless of where they live. With proper diagnosis, management and care, people with bleeding disorders can live perfectly healthy lives. Without treatment, the reality is that many will die young or, if they survive, suffer joint damage that leaves them with permanent disabilities. Only about 25% of the estimated 400\u2003000 people with haemophilia worldwide receive adequate treatment. The percentage is far lower for those with von Willebrand Disease (VWD) and the rarer bleeding disorders. The achievements of the WFH to close the gap in care for people with bleeding disorders are measureable over time by using three key indicators; the difference in the estimated and actual number of people known with bleeding disorders, the amount of treatment products needed <jats:italic>versus<\/jats:italic> that available, and the number of people born with bleeding disorders and the number who reach adulthood. There are five essential elements to achieve a sustainable national care programme: ensuring accurate laboratory diagnosis, achieving government support, improving the care delivery system, increasing the availability of treatment products, and building a strong national patient organization.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2011.08765.x","type":"journal-article","created":{"date-parts":[[2011,6,30]],"date-time":"2011-06-30T13:03:18Z","timestamp":1309438998000},"page":"704-714","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Haemophilia: provision of factors and novel therapies: World Federation of Hemophilia goals and achievements"],"prefix":"10.1111","volume":"154","author":[{"given":"Mark W.","family":"Skinner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,6,28]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.10327"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2010.02289.x"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05952.x"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2008.01797.x"},{"key":"e_1_2_6_6_1","volume-title":"Universal Data Collection Program (UDC) report 2003\/Vol.5\/No.1","author":"Centers for Disease Control Prevention (CDC)","year":"2003"},{"key":"e_1_2_6_7_1","unstructured":"Centers for Disease Control and Prevention (CDC)(2011)Universal Data Collection Program (UDC) Data Report.https:\/\/www2a.cdc.gov\/ncbddd\/htcweb\/UDC_Report\/UDC_Report.asp. Last accessed 12 May 2011."},{"key":"e_1_2_6_8_1","volume-title":"One stage Prothrombin Time (PT)test and Activated Partial Thromboplsatuin Time (APTT)Test: Approved guideline","author":"Clinical and Laboratory Standards Institute","year":"2008"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01625.x"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3148.2009.00963.x"},{"key":"e_1_2_6_11_1","unstructured":"European Directorate of the Quality of Medicines & HealthCare (EDQM)(2009)Proceedings of the International Symposium on the Optimal Clinical Use of Blood Components; 24\u201325 April 2009; Page 332 (http:\/\/www.edqm.eu\/medias\/fichiers\/Proceedings_Optimal_Clinical_Use_of_Blood_Componen.pdf)."},{"key":"e_1_2_6_12_1","volume-title":"Summary Report EHC Policy Roundtable on the Role of Patient Registries for People with Haemophilia","author":"European Haemophilia Consortium","year":"2007"},{"key":"e_1_2_6_13_1","unstructured":"European Medicines Agency(2011) London UK.http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/special_topics\/document_listing\/document_listing_000318.jsp&murl=menus\/special_topics\/special_topics.jsp&mid=WC0b01ac0580281bf0. Last accessed 12 April 2011."},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2002.00616.x"},{"key":"e_1_2_6_15_1","volume-title":"Guide to Developing a National Patient Registry","author":"Evatt B.","year":"2005"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01256.x"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1999.00317.x"},{"key":"e_1_2_6_18_1","volume-title":"Guide for the Assessment of Clotting Factor Concentrates for the Treatment of Hemophilia","author":"Farrugia A.","year":"2008"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.1991.tb13514.x"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2011.04214.x"},{"key":"e_1_2_6_21_1","doi-asserted-by":"crossref","unstructured":"Guh S. Grosse S.D. McAlister S. Kessler C.M.&Soucie J.M.(2011)Costs of care for privately insured males with hemophilia in the United States 2008. HTRS 2011 Annual Scientific Symposium Abstracts.Haemophilia 17 566.","DOI":"10.1016\/j.jval.2011.02.348"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.2001.00230.x"},{"key":"e_1_2_6_23_1","volume-title":"HIV and the Blood Supply: An Analysis of Crisis Decisionmaking","author":"Institute of Medicine","year":"1995"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2008.01933.x"},{"key":"e_1_2_6_25_1","volume-title":"Reproductive Health in Women with Bleeding Disorders. WFH Treatment of Hemophilia","author":"Kadir R.A.","year":"2009"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.1997.tb12024.x"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.1998.tb10093.x"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2010.02210.x"},{"key":"e_1_2_6_29_1","volume-title":"Diagnosis of Haemophilia and Other Bleeding Disorders: A Laboratory Manual","author":"Kitchen D.","year":"2010"},{"key":"e_1_2_6_30_1","first-page":"58","article-title":"Ultrasonic evaluation of the postpartum uterus in the management of postpartum bleeding","volume":"1981","author":"Lee C.Y.","year":"1981","journal-title":"Obstetrics and Gynecology"},{"key":"e_1_2_6_31_1","doi-asserted-by":"crossref","unstructured":"Lillicrap D.(2010)Genetic Characterization of Hemophilia and Implications for Novel Therapies. ASH Annual Meeting Abstracts 116: SCI\u20109","DOI":"10.1182\/blood.V116.21.SCI-9.SCI-9"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067659"},{"key":"e_1_2_6_33_1","volume-title":"World Federation of Hemophilia, Occasional Paper No 5. The Safety of Plasma\u2010Derived Versus Recombinant Concentrates","author":"Mannucci P.M.","year":"2004"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1647493"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06942.x"},{"key":"e_1_2_6_36_1","first-page":"16","article-title":"Haemophilia B gene therapy study in the UK. Late Breaking Abstracts from the WFH Haemophilia 2010 World Congress","volume":"2010","author":"Nathwani A.","year":"2010","journal-title":"Haemophilia"},{"key":"e_1_2_6_37_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.248.248","article-title":"Early Clinical Trial Results Following Administration of a Low Dose of a Novel Self Complementary Adeno\u2010Associated Viral Vector Encoding Human Factor IX In Two Subjects with Severe Hemophilia B","volume":"116","author":"Nathwani A.","year":"2010","journal-title":"Blood"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01643.x"},{"key":"e_1_2_6_39_1","volume-title":"Global Haemophilia Care Challenge and Opportunities. Plenary Presentation World Federation of Hemophilia XXV Congress","author":"O\u2019Mahony B.","year":"2002"},{"key":"e_1_2_6_40_1","volume-title":"Guide to the National Tenders for the Purchase of Clotting Factor Concentrates","author":"O\u2019Mahony B.","year":"2006"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-09-3879"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02752.x"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2008.01821.x"},{"key":"e_1_2_6_44_1","unstructured":"Prevention of Postpartum Hemorrhage Initiative Office of Health Infectious Diseases and Nutrition Bureau for Global Health(2007) Website 2007. Available athttp:\/\/www.pphprevention.org\/pph.php. Accessed 10 April 2011."},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.1995.tb00056.x"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2000.00446.x"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1975.tb01859.x"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.2147\/BS.S16120"},{"key":"e_1_2_6_49_1","first-page":"14","article-title":"Review of quality of life: menorrhagia in women with or without inherited bleeding disorders","volume":"2008","author":"Shankar M.","year":"2008","journal-title":"Haemophilia"},{"key":"e_1_2_6_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01280.x"},{"key":"e_1_2_6_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2008.01707.x"},{"key":"e_1_2_6_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2010.02285.x"},{"key":"e_1_2_6_53_1","first-page":"437","article-title":"Mortality among males with hemophilia: relations with source of medical care","volume":"96","author":"Soucie J.M.","year":"2000","journal-title":"Blood"},{"key":"e_1_2_6_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05110.x"},{"key":"e_1_2_6_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2009.02127.x"},{"key":"e_1_2_6_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2009.02131.x"},{"key":"e_1_2_6_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2010.02461.x"},{"key":"e_1_2_6_58_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2008.01721.x"},{"key":"e_1_2_6_59_1","unstructured":"United Nations(2010).United Nations Millennium Development Goals \u2013 Goal 4 Child Health. Available athttp:\/\/endpoverty2015org\/goals\/child\u2010health."},{"key":"e_1_2_6_60_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2003.00780.x"},{"key":"e_1_2_6_61_1","volume-title":"Minutes for the first meeting of the World Federation of Hemophilia","author":"World Federation of Hemophilia","year":"1963"},{"key":"e_1_2_6_62_1","volume-title":"Global Survey on Hemophilia","author":"World Federation of Hemophilia","year":"1999"},{"key":"e_1_2_6_63_1","volume-title":"Report on the Annual Global Survey 2000","author":"World Federation of Hemophilia","year":"2000"},{"key":"e_1_2_6_64_1","volume-title":"Report on the Annual Global Survey 2001","author":"World Federation of Hemophilia","year":"2001"},{"key":"e_1_2_6_65_1","volume-title":"Report on the Annual Global Survey 2002","author":"World Federation of Hemophilia","year":"2002"},{"key":"e_1_2_6_66_1","volume-title":"Improving Care Beyond Our Borders \u2013 A Twinning Guide for Hemophilia Treatment Centres","author":"World Federation of Hemophilia","year":"2002"},{"key":"e_1_2_6_67_1","volume-title":"Report on the Annual Global Survey 2003","author":"World Federation of Hemophilia","year":"2004"},{"key":"e_1_2_6_68_1","volume-title":"Report on the Annual Global Survey 2004","author":"World Federation of Hemophilia","year":"2005"},{"key":"e_1_2_6_69_1","volume-title":"Guidelines for the Management of Hemophilia","author":"World Federation of Hemophilia","year":"2005"},{"key":"e_1_2_6_70_1","volume-title":"Treatment for All: A Vision for Improvement","author":"World Federation of Hemophilia","year":"2006"},{"key":"e_1_2_6_71_1","volume-title":"Report on the Annual Global Survey 2005","author":"World Federation of Hemophilia","year":"2006"},{"key":"e_1_2_6_72_1","volume-title":"Report on the Annual Global Survey 2006","author":"World Federation of Hemophilia","year":"2007"},{"key":"e_1_2_6_73_1","volume-title":"Report on the Annual Global Survey 2007","author":"World Federation of Hemophilia","year":"2008"},{"key":"e_1_2_6_74_1","volume-title":"Patient Outreach Guide for Hemophilia and Other Bleeding Disorders","author":"World Federation of Hemophilia","year":"2008"},{"key":"e_1_2_6_75_1","volume-title":"Report on the Annual Global Survey 2008","author":"World Federation of Hemophilia","year":"2009"},{"key":"e_1_2_6_76_1","volume-title":"Sixth Global Forum on the Safety and Supply of Treatment Products for Bleeding Disorders Proceedings","author":"World Federation of Hemophilia","year":"2009"},{"key":"e_1_2_6_77_1","volume-title":"Accredited National Member Organizations of the WFH","author":"World Federation of Hemophilia","year":"2010"},{"key":"e_1_2_6_78_1","volume-title":"WFH Annual Report 2010","author":"World Federation of Hemophilia","year":"2011"},{"key":"e_1_2_6_79_1","volume-title":"Report on the Annual Global Survey 2009","author":"World Federation of Hemophilia","year":"2011"},{"key":"e_1_2_6_80_1","volume-title":"Developing a National Policy and Guidelines on the Clinical Use of Blood","author":"World Health Organization","year":"1998"},{"key":"e_1_2_6_81_1","volume-title":"Delivery of Treatment for Haemophilia, Report of a Joint WHO\/WFH\/ISTH Meeting. London, UK","author":"World Health Organization","year":"2002"},{"key":"e_1_2_6_82_1","volume-title":"WHO Model List of Essential Medicines; 16th list (updated) March 2010","author":"World Health Organization","year":"2010"},{"key":"e_1_2_6_83_1","volume-title":"WHO Model Formulary for Children 2010 based on the Second Model List of Essential medicines for Children 2009","author":"World Health Organization","year":"2010"},{"key":"e_1_2_6_84_1","volume-title":"WHO Essential Medicines Fact Sheet 325 (revised June 2010)","author":"World Health Organization","year":"2010"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2011.08765.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2011.08765.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T04:13:24Z","timestamp":1697429604000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2011.08765.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6,28]]},"references-count":83,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["10.1111\/j.1365-2141.2011.08765.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2011.08765.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6,28]]},"assertion":[{"value":"2011-06-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}